Profile data is unavailable for this security.
About the company
NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. It is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. It is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
- Revenue in USD (TTM)0.00
- Net income in USD-82.95m
- Incorporated2021
- Employees63.00
- LocationNKGen Biotech Inc3001 Daimler St,SANTA ANA 92705United StatesUSA
- Phone+1 (949) 396-6830
- Fax+1 (302) 636-5454
- Websitehttps://nkgenbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iterum Therapeutics PLC | 0.00 | -38.37m | 25.66m | 14.00 | -- | -- | -- | -- | -2.96 | -2.96 | 0.00 | -0.4743 | 0.00 | -- | -- | 0.00 | -82.44 | -118.12 | -108.84 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.51 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Unity Biotechnology Inc | 0.00 | -39.86m | 25.68m | 19.00 | -- | 0.9043 | -- | -- | -2.75 | -2.75 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -41.95 | -47.21 | -49.03 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Acasti Pharma Inc | 0.00 | -38.77m | 25.94m | 32.00 | -- | 0.4011 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| Qilian International Holding Group Ltd | 46.47m | -7.78m | 26.09m | 298.00 | -- | 0.6098 | -- | 0.5615 | -0.2176 | -0.2176 | 1.30 | 1.20 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| Biora Therapeutics Inc | 4.00k | -124.33m | 26.30m | 58.00 | -- | -- | -- | 6,573.92 | -8.57 | -8.56 | 0.0003 | -4.28 | 0.00009 | -- | 0.0048 | 68.97 | -293.45 | -122.84 | -- | -369.01 | -- | -- | -3,108,350.00 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| BioVie Inc | 0.00 | -43.27m | 26.70m | 18.00 | -- | 2.59 | -- | -- | -1.19 | -1.19 | 0.00 | 0.188 | 0.00 | -- | -- | 0.00 | -125.99 | -456.35 | -184.48 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.5764 | -- | -- | -- | -92.67 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -31.48m | 27.15m | 9.00 | -- | 0.7665 | -- | -- | -1.19 | -1.19 | 0.00 | 0.9719 | 0.00 | -- | -- | 0.00 | -77.74 | -72.06 | -84.92 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 27.30m | 3.00 | -- | 1.04 | -- | 63.29 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| NKGen Biotech Inc | 0.00 | -82.95m | 28.34m | 63.00 | -- | -- | -- | -- | -5.24 | -5.24 | 0.00 | -2.68 | 0.00 | -- | -- | 0.00 | -86.93 | -- | -111.69 | -- | -- | -- | -- | -- | -- | -0.6077 | -- | -- | -- | -- | -1,923.83 | -- | -- | -- |
| Lipocine Inc | -2.85m | -16.35m | 28.45m | 17.00 | -- | 1.39 | -- | -- | -3.11 | -3.11 | -0.5417 | 3.83 | -0.0942 | -- | -- | -167,695.30 | -54.02 | -39.32 | -58.16 | -45.87 | -- | -- | -- | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| America Great Health | 219.13k | -859.20k | 29.56m | 7.00 | -- | -- | -- | 134.89 | -0.00004 | -0.00004 | 0.00001 | -0.0002 | 0.6746 | 0.0721 | 18.16 | 31,304.29 | -265.62 | -543.96 | -- | -- | 95.92 | -247.36 | -393.74 | -1,193.55 | 0.035 | -1.37 | -- | -- | 95.23 | -- | 84.35 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -47.99m | 29.85m | 40.00 | -- | 5.30 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
| Aprea Therapeutics Inc | 583.24k | -14.29m | 30.35m | 7.00 | -- | 1.23 | -- | 52.05 | -4.00 | -4.00 | 0.1613 | 4.89 | 0.0221 | -- | -- | 83,320.00 | -54.11 | -68.66 | -63.19 | -77.19 | -- | -- | -2,449.55 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| Singular Genomics Systems Inc | 2.91m | -94.82m | 30.44m | 255.00 | -- | 0.1698 | -- | 10.46 | -1.30 | -1.30 | 0.04 | 2.42 | 0.0098 | 0.2182 | 3.94 | 11,415.69 | -31.96 | -- | -33.80 | -- | -19.17 | -- | -3,257.30 | -- | 9.77 | -- | 0.0474 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -17.19m | 31.16m | 29.00 | -- | -- | -- | -- | -0.4079 | -0.4079 | 0.00 | -0.0803 | 0.00 | -- | -- | 0.00 | -271.62 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
Data as of May 10 2024. Currency figures normalised to NKGen Biotech Inc's reporting currency: US Dollar USD
15.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Meteora Capital LLCas of 31 Dec 2023 | 1.60m | 7.30% |
| Polar Asset Management Partners, Inc.as of 31 Dec 2023 | 1.08m | 4.93% |
| Sandia Investment Management LPas of 31 Dec 2023 | 442.62k | 2.02% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 53.80k | 0.25% |
| Geode Capital Management LLCas of 31 Dec 2023 | 45.85k | 0.21% |
| Millennium Management LLCas of 31 Dec 2023 | 18.39k | 0.08% |
| G1 Execution Services LLCas of 31 Mar 2024 | 16.91k | 0.08% |
| Sequoia Financial Advisors LLCas of 31 Mar 2024 | 16.00k | 0.07% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 15.72k | 0.07% |
| NYL Investors LLCas of 31 Mar 2024 | 10.00k | 0.05% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
